|
Dec 13
|
Vertex Stock Hits Record High on Phase 2 Study Results and Gene-Editing Deal
|
|
Dec 13
|
Vertex Pharmaceuticals Shares Jump After Promising Study Results for Pain Medication
|
|
Dec 13
|
Why Vertex Stock Is Soaring Today
|
|
Dec 13
|
Rebel's Edge - December 13: $PFE, $VRTX, $PLAB, and Bowl Games
|
|
Dec 13
|
Vertex Pharmaceuticals Jumps on Pain Medication Success: How to Play It
|
|
Dec 13
|
Better Growth Stock: Vertex Pharmaceuticals or Exact Sciences?
|
|
Dec 13
|
UPDATE 2-Vertex's non-opioid nerve pain treatment succeeds in mid-stage trial
|
|
Dec 13
|
Vertex Announces Positive Results From Phase 2 Study of VX-548 for the Treatment of Painful Diabetic Peripheral Neuropathy
|
|
Dec 13
|
Vertex builds case for non-opioid pain drug ahead of key study readouts
|
|
Dec 13
|
At ASH, doctors acclaim new sickle cell gene therapies, but are cautious on details
|
|
Dec 12
|
Here's What The FDA Approval Of Gene Editing For Sickle Cell Means For CRSP Stock And The Future Of Medicine
|
|
Dec 10
|
3 Unstoppable Stocks to Buy Right Now
|
|
Dec 10
|
Vertex Pharmaceuticals Just Proved Something Big to Investors. Time to Buy?
|
|
Dec 9
|
Forget the "Magnificent Seven": Buy This Stock Instead
|
|
Dec 9
|
2 Superior Growth Stocks Up 23% and 105% in 2023 to Buy Now and Hold for Years
|
|
Dec 8
|
Vertex, CRISPR Therapeutics Get FDA Approval for First CRISPR Gene-Editing Therapy in US
|
|
Dec 8
|
Crispr Stock Whipsaws Lower After FDA Approves Gene-Editing Treatment
|
|
Dec 8
|
FDA approves gene-editing therapy for sickle cell disease
|
|
Dec 8
|
Vertex, Bluebird Both Get FDA Approval for Sickle Cell Gene Therapies
|
|
Dec 8
|
FDA Approves First Two Sickle Cell Gene Therapies, bluebird bio Shares Tumble
|